Global Lymphedema Treatment Market - 2024-2031

Global Lymphedema Treatment Market - 2024-2031

The global lymphedema treatment market reached US$ 1.1 billion in 2023 and is expected to reach US$ 2.3 billion by 2031 growing with a CAGR of 9.5% during the forecast period 2024-2031.

Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid that's usually drained through the body's lymphatic system. It most commonly affects the arms or legs, but can also occur in the chest wall, abdomen, neck, and genitals.

Lymph nodes are an important part of the lymphatic system. Lymphedema can be caused by cancer treatments that remove or damage the lymph nodes. Any type of problem that blocks the drainage of lymph fluid can cause lymphedema.

Lymphedema treatment typically includes a combination of physical therapy and garments or bandaging that moves fluid from areas affected by lymphedema.

Market Dynamics: Drivers

Increasing Technological Advancements for Lymphedema Treatment

The demand for the global lymphedema market is driven by multiple factors. One of the key factors is the technological advancements in the healthcare system. Lymphedema is a chronic condition that is usually caused by insufficient lymphatic drainage.

The innovative technological advancements by key companies help to drive market growth. These effective advancements help to transform research discoveries into new treatments and improve care for millions of people with lymphedema. For instance, in October 2022, ImpediMed Limited announced the expansion of the use of its SOZO Digital Health Platform at leading cancer centers dedicated to reducing the impact of lymphedema on breast cancer patients.

Moreover, key players introducing advanced research & developments in treating lymphedema and launching new therapies & drugs would drive this market growth. For instance, in April 2023, AIROS Medical, Inc. announced that it received U.S. Food and Drug Administration (FDA) clearance to market a new peristaltic pneumatic compression device, truncal garments for lymphedema treatment.

Also, in April 2022, Koya Medical announced the U.S. commercial availability of its Dayspring active compression system for the treatment of lymphedema and venous diseases in the lower extremities. Dayspring is the first non-pneumatic active dynamic compression treatment cleared by the U.S. Food and Drug Administration (FDA). Thus, the above factors help to boost the market growth.

Restraints

Factors such as the high cost of the treatment procedure, side effects associated with stem cell therapy treatment, limited treatment options, and lack of awareness & diagnosis among individuals, are expected to hamper the market.

Segment Analysis

The global lymphedema treatment market is segmented based on type, treatment, end users, and region.

The decongestive therapy segment accounted for approximately 43.2% of the global lymphedema treatment market share

The decongestive therapy segment is expected to hold the largest market share over the forecast period. The rising clinical trials of treatment therapy globally have contributed to the growing demand for lymphedema treatment. According to clinicalTrials.gov, in July 2022, Gulhane School of Medicine conducted a clinical trial on the Effect of Metabolic Syndrome on Complex Decongestive Physiotherapy Outcomes in Lymphedema Patients. The aim is to compare the effectiveness of complex decongestive physiotherapy (KBF) in patients with and without metabolic syndrome.

Moreover, key players in the industry research studies in the treatment of lymphedema would drive this segment growth. For instance, in July 2023, Cairo University conducted a clinical trial on the Effect Of Complete Decongestive Therapy on Carpal Tunnel Syndrome Post Upper Limb Lymphedema (CDT). The patients receives complete decongestive therapy in the form of intermittent pneumatic compression, exercising, bandaging, and manual lymphatic drainage. Thus, the above factors help to accelerate the market growth.

Also, in May 2022, PureTech Health announced the presentation of additional data for PureTech’s LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference. LYT-100 demonstrated a lower incidence of adverse events (AEs) compared to pirfenidone at comparable exposure levels and observed improved tolerability of LYT-100. It is the potential treatment of conditions involving inflammation and fibrosis, including lung disease and disorders of lymphatic flow, such as lymphedema.

Geographical Analysis

North America accounted for approximately 41.2% of the global lymphedema treatment market share

North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of lymphedema, and rising breast cancer, in the U.S., and Canada driving the market growth.

As per Lymphatic Education & Research Network in 2024, up to 250 million people worldwide have lymphedema (LE) with an estimated 10 million living with lymphedema (LE) in the United States, up to 30% of breast cancer survivors acquire debilitating LE.

Moreover, in this region, a major key player's partnerships & collaborations, well-advanced healthcare system, and new product launches would propel this market growth. For instance, in June 2023, PAUL HARTMANN AG announced its partnership with Sigvaris for the innovative compression wraps and liners range that are used as compression therapy for the treatment of lymphedema.

Also, in October 2022, ImpediMed announced the U.S. launch of a lymphedema prevention program with Genesis Care, a global organization dedicated to the care of cancer patients.

Similarly, in March 2024, NHLBI helps launch the first NIH National Commission on Lymphatic Diseases. The creation of this lymphatics commission is a gratifying and revolutionary step in this very important and relatively neglected field of research.

Market Segmentation

By Type
• Primary Lymphedema
• Secondary Lymphedema

By Treatment
• Stem Cell Therapy
• Decongestive therapy
• Surgery
• Drug Therapy
• Laser Therapy
• Others

By End Users
• Hospital
• Clinics
• Ambulatory Surgical Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the lymphedema market include Kite Pharma, Johnson, and Johnson, Sanofi S.A, LGM Pharma, Hubei Xunda Pharma, Sigma Aldrich, Midas Pharma, Oishi Koseido Co. Ltd, Glentham Life Sciences, Taro Pharmaceuticals among others.

Key Developments

In August 2023, Calamos Advisors LLC made a significant investment in Tactile Systems Technology, Inc. by acquiring 60,861 shares of the company’s stock. The purchase amounted to approximately $999,000 and represented 0.26% ownership of Tactile Systems Technology. Tactile Systems Technology is a medical technology company dedicated to developing innovative devices for the treatment of conditions such as lymphedema, venous disorders, and pulmonary secretions retention.

In June 2022, Hyperice, launched Normatec 3, the next evolution of the iconic Normatec series which uses dynamic air compression to advance everyday wellness and helps aid in faster recovery, and improved training. Normatec was developed to help people undergoing breast cancer treatment who often suffer from lymphedema caused by removal or damage to their lymph nodes.

In May 2022, Hospice charity partners with AECC University College to provide new lymphoedema service. The initiative follows the success of Lewis-Manning Hospice Care’s pilot mobile lymphoedema clinics by bringing its services closer to people’s homes and making the service accessible and easy.

Why Purchase the Report?
• To visualize the global lymphedema treatment market segmentation based on type, treatment, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global lymphedema treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global lymphedema treatment market report would provide approximately 69 tables, 70 figures, and 182 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies